New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Brought to you by 
Biogen, AGTC team up in gene therapy deal; deal terminated
Jul 2015
Executive Summary
Biogen Inc. received worldwide rights to commercialize Applied Genetic Technologies Corp.'s Phase I X-linked retinoschisis (XLRS) gene therapy program and preclinical candidate for X-linked retinitis pigmentosa (XLRP).
Deal Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Intra-Biotech Deal
- Includes Royalty or Profit Split Information
- Includes Equity
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biogen, AGTC team up in gene therapy deal; deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice